… and those of the parasitic protozoon Trypanosoma cruzi, the causative agent of Chagas …
an approach that included directly probing the T. cruzi CYP51 active site with a library of …

… The biological cycle host-environment of the parasite Trypanosoma cruzi was elucidated by
Carlos Chagas in 1909 [1]. The disease caused by this microorganism is known as Chagas …

… The crystal structures of T. cruzi FPPS with some of these compounds have been recently
solved [… Chagas disease is a parasitic illness produced by Trypanosoma cruzi, endemic from …

… More recently, 2,3-dihydroimidazo[1,2-a]benzimidazole derivatives demonstrated promising
activity against Leishmania donovani and Trypanosoma cruzi. In this context, it seems very …

… cruzi protozoan infection, represents a major … -Trypanosoma cruzi derivatives involving
nitroheterocycles, we report herein the synthesis of ten 1-substituted 2-nitropyrrole compounds …

… screened for its ability to affect the viability of Trypanosoma cruzi parasites. 5-(3-(Benzyloxy)-…
) proved to be the most active compound against intracellular forms of T. cruzi (pIC 50 = 6.4) …

… The substituents at the benzene ring moiety (Y) in the nitro-heterocyclic compounds
evaluated in this study exerted a distinct influence in the calculated hydrophobicity of the whole …

… classes of heterocyclic compounds were prepared and … heterocyclic 1,2,3-triazole led to
bioactive quinone-based triazoles. Among the derivatives investigated so far, three compounds …

… The disease is caused by the Trypanosoma Cruzi parasite, to which there is unmet need
for more effective treatments. Small molecule inhibitors for the Trypanosoma Cruzi parasite …

… in Latin America, caused by Trypanosoma cruzi. The drugs used for the … compounds with
potential clinical utility. An overview of a number of natural naphthoquinones tested against T…